Neuland Laboratories Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/64vx63hikfglrwsfz94zpj1l.pdf

Key Takeaways


CMS: The Growth Engine That Sputtered

Saharsh Davuluri: "One of the reasons why the growth is only 5% is because we have also had offset due to the degrowth of one of our largest CMS molecules this year... about Rs. 50-Rs. 60 crores of revenue which we were steadily recognizing in the previous years, we have not recognized this year and this growth happened despite that number."

Prime & Specialty: A Tale of Two Portfolios


Margins & Costs: Squeezed, With a Mix-Shift Offset

Sucheth Davuluri: "There is a lot of uncertainty coming out of the... Russia-Ukraine conflict as well as what is happening in China, so we have seen disruption in supply... we have seen a steep increase in prices of certain raw materials which is impacting our margins."

Lumpiness: A Structural Feature, Not a Bug

Saharsh Davuluri: "I think for us, the way this lumpiness would reduce, it may never go away is when more of these molecules which are in development stage become commercial molecules and obviously when they become commercial molecules, they will start contributing steady recurring revenues..."

DMF Pipeline & Long-Term Bets

Sucheth Davuluri: "I think what is important to us that in the next few years, we build a very high-quality business... to file DMF which are specialty DMFs on the API side, so that we are able to protect our margins, we don't lose products or lose market share because of too much competition and customers who are not willing to stick to our high-quality business."

Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Levetiracetam volume recoveryVolumes expected to recover"Coming quarters"
CMS molecules entering commercial stagePerhaps 2 more in FY23, remainder in the year afterFY23 and FY24
Working capital normalizationSome dip expected as inventory rationalizes"Subsequent quarters"
GDS growth from patent expiriesApixaban, Paliperidone, Rivaroxaban launches in certain marketsFY23
Linezolid injectable commercial revenueNear-term revenue from API market of Rs. 15–20 croresNear term
4 specialty DMFs (ex-Linezolid) commercial revenueCommercial revenues expected5–6 years

Key Metrics

MetricQ4 FY22
CMS revenue (full year)~₹300 cr, highest ever
CMS commercial revenue (full year)~₹114 cr, recurring
CMS development revenue (full year)~₹168 cr, project-based
CMS commercial revenue (quarter)~₹34 cr, recurring
CMS development revenue (quarter)~₹38 cr, project-based
CMS molecules moved to commercial stage1 molecule in Q4, 2 total so far
DMFs filed2 in Q4 (Elagolix Sodium, Linezolid), 5 for FY22
CAPEX spent (FY22)₹95 cr
CAPEX planned (FY23)₹100 cr, of which ₹54–₹55 cr for CMS
Net gearing ratio0.3x
Net debt₹212 cr, up from ~₹152 cr
Unit III capacity utilization~40%
Unit I and II capacity utilization70–80%
Unit III revenue (FY21)₹80 cr plus
Lost CMS business (annual revenue not recognized)₹50–₹60 cr (per management)